Detecting and tracking age-related macular degeneration
Sign up today and learn more about MacuLogix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About MacuLogix Stock
MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.
Co-founder and Chief Scientific Officer
Gregory R. Jackson